At the news
? NEUTRALIMPACT 3/10 PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET
The PTAB granted institution of post-grant review (PGR2026-00059) on Neurocrine's petition challenging Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. The decision is interlocutory and does not cancel any claims; a final written decision is expected within about a year.
- PTAB granted institution of PGR2026-00059 on November 10, 2026
- Patent U.S. 12569491 covers methods for treating testicular and ovarian adrenal rest tumors
- Patent owner is Spruce Biosciences, Inc.; petitioner is Neurocrine Biosciences, Inc.
- Institution is interlocutory, no claims have been cancelled
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access